Verweij J, Catimel G, Sulkes A, Sternberg C, Wolff I, Aamdal S, van Hoesel Q
Rotterdam Cancer Institute, The Netherlands.
Eur J Cancer. 1995;31A Suppl 4:S21-4. doi: 10.1016/0959-8049(95)00362-m.
Docetaxel has been evaluated in six tumour types in a total of 189 patients entered into phase II studies. Treatment consisted of a 1 h intravenous infusion of docetaxel 100 mg/m2 repeated every 3 weeks. No premedication was administered for possible hypersensitivity reactions. Docetaxel was found to be effective as first-line chemotherapy for head and neck cancer (response rate 44%) gastric cancer (23%) and melanoma (14%) and as second-line chemotherapy for soft tissue sarcomas (21%; 95% confidence interval: 7.5%-43.7%). The results in colorectal and renal cancer were disappointing, with response rates of less than 10%. The most frequent adverse effects were alopecia (81%), grade III-IV leukocytopenia of short duration (66%) and skin reactions (52%). Hypersensitivity reactions were mild and occurred in 26% of patients. Docetaxel is an important new drug in the treatment of solid tumours.
多西他赛已在6种肿瘤类型中进行了评估，共有189例患者进入II期研究。治疗方案为每3周重复一次静脉输注多西他赛100mg/m²，持续1小时。未针对可能的过敏反应进行预处理。多西他赛被发现对头颈部癌（缓解率44%）、胃癌（23%）和黑色素瘤（14%）作为一线化疗有效，对软组织肉瘤作为二线化疗有效（21%；95%置信区间：7.5%-43.7%）。结直肠癌和肾癌的结果令人失望，缓解率低于10%。最常见的不良反应是脱发（81%）、短期III-IV级白细胞减少（66%）和皮肤反应（52%）。过敏反应较轻，26%的患者出现。多西他赛是实体瘤治疗中的一种重要新药。
